Drug Trial Radar · NCT00222053
IFM 99-02 Thalidomide in Myeloma
Last checked: Nov 20, 2026Latest source record: Apr 2, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Apr 2000
Primary completion
Sep 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
Conditions
- Multiple Myeloma
Interventions
ThalidomideDrug
Per os thalidomide
BiphosphonatesDrug
Biphosphonates
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of responseTime frame: 3 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Médecine Interne, CHU Purpan
Toulouse, France
Médecine Interne, Hôpital Rangueil
Toulouse, France
Rhumatologie, CHU Purpan
Toulouse, France
Rhumatologie, CHU Rangueil
Toulouse, France
Service d'hématologie, CHU Purpan
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.